×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:VTVT

vTv Therapeutics Stock Forecast, Price & News

$0.69
-0.02 (-2.83%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.68
$0.73
50-Day Range
$0.39
$0.79
52-Week Range
$0.38
$2.27
Volume
55,818 shs
Average Volume
253,363 shs
Market Capitalization
$61.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

vTv Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
699.9% Upside
$5.50 Price Target
Short Interest
Bearish
9.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.31) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.63 out of 5 stars

Medical Sector

892nd out of 1,433 stocks

Pharmaceutical Preparations Industry

441st out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

vTv Therapeutics logo

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Stock News Headlines

Aravive Appoints Rudy Howard as Chief Financial Officer
3 Oversold Biotech Stocks to Buy Now
vTv Therapeutics Announces CEO Transition
vTv Therapeutics Shares Updated Corporate Presentation
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTVT
Employees
9
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/07/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+699.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-12,990,000.00
Net Margins
-313.93%
Pretax Margin
-416.76%

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
($0.11) per share

Miscellaneous

Free Float
88,776,000
Market Cap
$61.91 million
Optionable
Not Optionable
Beta
-1.55














vTv Therapeutics Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" vTv Therapeutics stock.
View analyst ratings for vTv Therapeutics
or view top-rated stocks.

What is vTv Therapeutics' stock price forecast for 2022?

2 brokers have issued 12-month target prices for vTv Therapeutics' stock. Their VTVT stock forecasts range from $5.00 to $6.00. On average, they expect vTv Therapeutics' share price to reach $5.50 in the next twelve months. This suggests a possible upside of 699.9% from the stock's current price.
View analysts' price targets for vTv Therapeutics
or view top-rated stocks among Wall Street analysts.

How has vTv Therapeutics' stock price performed in 2022?

vTv Therapeutics' stock was trading at $0.9950 at the beginning of the year. Since then, VTVT stock has decreased by 30.9% and is now trading at $0.6876.
View the best growth stocks for 2022 here
.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for vTv Therapeutics
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) posted its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company earned $2 million during the quarter.
View vTv Therapeutics' earnings history
.

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the following people:
  • Ms. Deepa Prasad, Strategic Advisor (Age 42, Pay $667.13k)
  • Mr. Richard S. Nelson, Interim CEO & Director (Age 52)
  • Mr. Barry Brown, Chief Accounting Officer (Age 61)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Vanessa McDade, Chief Admin. Officer
  • Mr. David M. Lambert III, Sr. VP & Gen. Counsel

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), (CGC), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $0.69.

How much money does vTv Therapeutics make?

vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $61.91 million and generates $4.01 million in revenue each year. The biotechnology company earns $-12,990,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does vTv Therapeutics have?

vTv Therapeutics employs 9 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for vTv Therapeutics is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.